세포은행 아웃소싱 - 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The cell banking outsourcing market is expected to register a CAGR of 16.9% over the forecast period.

COVID-19 significantly impacted the growth of the cell banking outsourcing market. The lockdown measures restricted stem cell procurement and donation across the globe. For instance, according to the study published in Bone Marrow Transplantation, October 2021, it was observed that due to the implementation of national lockdowns, international border closures, and aircraft and train circulation limitations, shutting down of cell banks made it more challenging to obtain stem cells from foreign and domestic donors. However, with the increased coronavirus cases, the use of stem cells increased during the pandemic for treating and restoring lung tissues. For instance, according to an article published in Molecular Biomedical in February 2022, it was observed that mesenchymal stem cells showed promising results in clinical trials for treating COVID-19 disease by modulating the immune system. In addition, human amniotic epithelial cells (hAECs) and human mesenchymal stromal cells (hAMSCs) were used in preclinical studies and clinical trials against respiratory diseases. They were shown to reduce the inflammatory response and restore the pulmonary tissue in lung injury in vivo models. The use of stem cells increased the demand for cell banking services. Thus, the studied market witnessed growth and is expected to gain its full potential over the forecast period.

Factors such as the growing demand for cell therapies, increasing awareness of stem cell banking, and the rising burden of chronic diseases are expected to boost market growth over the forecast period.

The increasing incidence of chronic diseases among the population raises the need for effective biotechnology-based products or regenerative medicines. It is anticipated to boost the demand for cell banking services for storing stem cells, propelling the market growth. For instance, according to the 2022 statistics published by the Alzheimer's Association, about 6.5 million people were living with Alzheimer's in America in 2022, projected to reach 13.8 million by 2060. Also, according to the BHS England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. According to an article published in BMJ Global Health in March 2022, spinal muscular atrophy (SMA) affects approximately 250-300 newborns annually in Brazil. Thus, the high burden of heart disease and Alzheimer's among the population is anticipated to increase the company's focus on developing advanced cell therapy, thereby bolstering market growth.

Furthermore, the increasing awareness among the population regarding the use of stem cells and the benefits of storing them for the future further propelled the demand for stem cell banking, contributing to market growth. For instance, according to an article published in the Annals of the Romanian Society of Cell Biology in May 2021, a cross-sectional questionnaire was asked to the parents on the basics of their knowledge, awareness, and acceptance regarding stem cell banking in Delhi-NCR. It was observed that 96.4% of parents were aware of stem cell banking, and 84.5% were completely familiar with the storage of umbilical cord blood. Also, about 45% of parents believe that stem cell banking is vital as it will aid in treating serious diseases in the future. In comparison, 68% of individuals were interested in stem cell banking and wanted to know more about how stem cells are used.

Moreover, the growing government initiatives to accelerate the research and development of stem cell therapy are expected to increase the demand for stem cell banking outsourcing to preserve stem cells for future use. For instance, in February 2022, the Government of India assisted in establishing state-of-the-art stem cell research facilities in 40 premier medical research and educational institutes to promote the study and development of regenerative medicine in the nation.

Therefore, owing to the factors above, the studied market is expected to grow over the forecast period. However, the high cost of therapies and legal and changing ethical issues during collection will likely impede the growth of the cell banking outsourcing market over the forecast period.

Cell Banking Outsourcing Market Trends

Induced Pluripotent Stem Cell Banking Segment is Expected to Hold a Major Share in the Market Studied.

Human pluripotent stem cells, such as induced pluripotent stem cells (iPSCs), provide unprecedented opportunities for cell therapies to treat intractable diseases and injuries. iPSC is created from skin or blood cells reprogrammed into an embryonic-like pluripotent state. It allows the generation of an infinite supply of any human cell required for therapeutic applications.

The pluripotent stem cell banking segment is expected to witness significant growth in the cell banking outsourcing market over the forecast period owing to factors such as the rising adoption of iPSC for treating cancers and growing product launches.

According to an article published in Stem Cell Research in February 2021, pluripotent stem cell research and innovation are increasingly employed to model development and disease, conduct drug testing and toxicological analyses, and generate cellular therapeutic solutions. Additionally, as per an article published in Dovepress in January 2021, it was observed that the ability of cancer stem cells to silence cell surface signals could help the immune system. It can recognize tumor locations and prevent tumor cargo from adhering to healthy cells, thus preventing their transformation. In addition, as per the same source, induced pluripotent stem cells (iPSCs) can be used to immunize and vaccinate people against tumor cells in the future due to surface-antigen similarity between iPSCs and cancer cells. Thus, increasing research studies related to iPSCs are expected to increase segment growth over the forecast period.

Furthermore, the rise in funding for iPSC research is also expected to propel the segment growth. For instance, according to the data published by NIH, in May 2022, the government funded an estimated USD 740 million to support the research and development of induced pluripotent stem cells in the United States in 2022, compared to USD 713 million in 2021. Such a huge investment in iPSC is anticipated to increase its adoption, thereby driving the demand for banking services.

Moreover, the growing company provides induced pluripotent stem cell services to companies and other research institutes for clinical research, contributing to the segment growth. For instance, in September 2021, I Peace, Inc. is planning to launch its clinical-grade personalized iPSC banking service in the United States. This launch assists the company in expanding its stem cell banking services with its novel system technology. It is how to massively and simultaneously produce clinical-grade iPSCs from many donors in a single facility. In addition, the company is also planning to produce up to a few thousand lines of clinical-grade iPSCs in a year by 2025.

Therefore, owing to the factors above, the studied segment is expected to grow over the forecast period.

North America is Expected to Hold the Significant Market Share Over the Forecast Period

North America is expected to hold a significant market share over the forecast period. It is due to factors such as the rising prevalence of chronic diseases, increasing development of cell therapy or gene therapy-based products, growing research funding for stem cells, and the presence of key market players.

The rising number of stem cell-based research studies for treating various chronic diseases, such as type 1 diabetes (T1DM), Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, heart disease, and others, is the key factor driving the segment's growth. For instance, as per an article published in Stem Cell Research and Therapy in July 2022, it was observed that mesenchymal stem cells (MSCs) are the most promising. It can develop into dopaminergic neurons and release neurotrophic factors, thus treating neurodegenerative illnesses. Also, according to an article published in Frontiers in Endocrinology in March 2022, it was observed that stem cells could effectively cure T1DM by restoring immunotolerance and maintaining islet-cell activity. Stem cell transplantation is one of the most promising alternatives for treating T1DM. Thus, such research studies are anticipated to increase the adoption of stem cell-based therapies and drugs for treating various diseases. It, in turn, is anticipated to fuel the demand for cell banking services, bolstering the market growth.

The increasing number of stem cell research studies and their related funding are also contributing to the segment's growth. For instance, according to the data published by NIH, in May 2022, about USD 2,279 million was funded by the government for stem cell research in 2022 in the United States, compared to USD 2,186 million in 2021. These types of funding are anticipated to increase the development and availability of effective stem cell medicines for treating various chronic diseases among the population, thereby propelling market growth.

Furthermore, the growing number of companies manufacturing banking services centers and providing cell banking outsourcing services in the region is also contributing to the market growth. For instance, in September 2021, STEMCELL Technologies launched human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell. These services provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices.

Therefore, owing to the factors above, the studied market is expected to grow over the forecast period.

Cell Banking Outsourcing Industry Overview

The market for cell banking outsourcing is moderately competitive. The market is driven by the rise in the adoption of cell banking services, the rise in the launch of new biopharmaceutical drugs, and the rise in partnerships between key players. Some of the key companies in the market are Charles River Laboratories, Inc., Merck KGaA, Cryo-Cell International Inc., Clean Biologics, GBI, and LifeCell International Pvt. Ltd, SGS Life Sciences, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Demand For Cell Therapies
  • 4.2.2 Increasing Awareness for Stem Cell Banking
  • 4.2.3 Rise in Burden of Chronic Diseases
• 4.3 Market Restraints
  • 4.3.1 High Cost of Therapies
  • 4.3.2 Legal and Changing Ethical Issues During Collection
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Suppliers
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Bank Type
  • 5.1.1 Master Cell Banking
  • 5.1.2 Working Cell Banking
  • 5.1.3 Viral Cell Banking
• 5.2 By Cell Type
  • 5.2.1 Stem Cell Banking
    • 5.2.1.1 Cord Stem Cell Banking
    • 5.2.1.2 Embryonic Stem Cell Banking

• 5.2.1.3 Adult Stem Cell Banking
• 5.2.1.4 Dental Stem Cell Banking
• 5.2.1.5 Induced Pluripotent Stem cell Banking
• 5.2.2 Non-stem Cell Banking
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Charles River Laboratories, Inc.
  • 6.1.2 Merck KGaA
  • 6.1.3 Cryo-Cell International Inc.
  • 6.1.4 Clean Biologics
  • 6.1.5 Cordlife Group Limited
  • 6.1.6 Cryoviva India
  • 6.1.7 GBI
  • 6.1.8 LifeCell International Pvt. Ltd
  • 6.1.9 Lonza
  • 6.1.10 Reliance Life Sciences
  • 6.1.11 SGS Life Sciences
  • 6.1.12 Texcell
  • 6.1.13 Wuxi Apptec

7 MARKET OPPORTUNITIES AND FUTURE TRENDS